Global private equity and venture capital news and research

Posts Tagged ‘Caxton Alternative Management’

22 April 2014

Vivo Capital leads $58.5m Series D for ProNAi Therapeutics

biotech_lrg Nucleic acid therapeutics developer ProNAi Therapeutics has secured $59.5m in a Series D round led by venture capital firm Vivo Capital.

Legals & Terms of UsePrivacy Policy

AltAssets is registered as a trademark of Investor Networks Limited (06695690).
Registered Office: WeWork 4001, 1 Fore Street, London, EC2Y 5EJ
Content is © AltAssets 2000-2016